Trial Profile
Validation of a Kinetic Model of Erlotinib
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Erlotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Pharmacokinetics
- 29 Sep 2016 New trial record